This invention offers a new approach to managing otitis media. The vaccine is composed of lipooligosaccharide, isolated from the surface of strains of nontypeable H. influenzae and treated with hydrazine to remove esterified fatty acids, covalently conjugated to an immunogenic carrier, such as tetanus toxoid. The conjugates have been shown to be nontoxic by the limulus amebocyte assay, rabbit pyrogen test, and in a mouse lethal toxicity test. Antisera raised in rabbits immunized with the conjugate is bactericidal. It is an autoimmune disease in which the immune system produces antibodies that attack the body's own insulin-manufacturing cells in the pancreas.
Patients require daily injections of insulin to regulate blood sugar levels.
This invention relates to a collection of potential fat-soluble vitamins that may coordinate animal metabolism and development. The invention and others of its compositions can be characterized as likely physiological effectors that may represent essential components for human nutrition and cell growth. Thus, the invention suggests that it may coordinate cell physiology through RXR-dependent hormone signaling pathways. Presently available chelating agents lack specificity for their intended targets or do not adequately bind the chelated metal ion. These substituted DOTAs have a strong affinity for a number of metal ions.